Exploring the critical therapeutic window: Dose-frequency optimization of human umbilical cord mesenchymal stem cells for preclinical asthma treatment

doi:10.4252/wjsc.v17.i9.109715

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 9

This Article

(58)

(47)

(0)

(25)

(738)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Stem Cells. Sep 26, 2025; 17(9): 109715
Published online Sep 26, 2025. doi: 10.4252/wjsc.v17.i9.109715

Full Size Figure Download Figure

Figure 1 Schematic flow diagram of anti-asthma experiment with different dosages of human umbilical cord blood-derived mesenchymal stem cell treatment. OVA: Ovalbumin; HUC-MSCs: Human umbilical cord blood-derived mesenchymal stem cells.

Citation: Chen QH, Zheng JY, Zhu YQ, Zhang JY, Lin CY, Zhuang XE, Cheng J, Huang XY. Exploring the critical therapeutic window: Dose-frequency optimization of human umbilical cord mesenchymal stem cells for preclinical asthma treatment. World J Stem Cells 2025; 17(9): 109715
URL: https://www.wjgnet.com/1948-0210/full/v17/i9/109715.htm
DOI: https://dx.doi.org/10.4252/wjsc.v17.i9.109715

Chen QH, Zheng JY, Zhu YQ, Zhang JY, Lin CY, Zhuang XE, Cheng J, Huang XY. Exploring the critical therapeutic window: Dose-frequency optimization of human umbilical cord mesenchymal stem cells for preclinical asthma treatment. World J Stem Cells 2025; 17(9): 109715 [PMID: 41025110 DOI: 10.4252/wjsc.v17.i9.109715]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.